Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2467

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2467
---
.
    We are skilled at objectively directing internal resources, and at leveraging external resources (such as CROs and CMOs), in order
    to progress product candidates in accordance with well-defined criteria for advancement within a lean cost structure.

    ●
    Building
    a diverse portfolio of product candidates. We are evidence-based and program agnostic, meaning that our resources are driven strictly
    by program progress and milestone achievements. Our approach is to develop multiple diverse programs in parallel. Our success is
    not dependent on any one particular program, disease area or indication, which mitigates business risk, and allows us the flexibility
    to opportunistically develop product candidates, regardless of therapeutic area. We believe that this model ensures that we remain
    focused on assets with the most promise. The unifying theme in our portfolio is to address significant unmet medical needs by commercializing
    innovative therapeutic products, if approved.

    ●
    Providing
    attractive economic upside to our partners at research universities and medical centers. We have a structure wherein Ocean Biomedical
    houses each of its programs in a subsidiary. We believe this structure is optimal to provide attractive economic incentives to the
    discovering institution and its researchers. Our subsidiary structure is intended to enable us to offer equity in future programs
    to the licensing institution and the researchers who discover our product candidates. We believe this structure will make us a partner
    of choice for both institutions and researchers and aligns our interests with theirs toward the goal of maximum returns.

    ●
    Employing
    a multi-disciplinary approach to drug discovery and development across our programs. Our business model is based on bringing together
    the appropriate disciplines and expertise needed for each of our programs and leveraging learnings across programs and disease areas.
    Common ties between many diseases are becoming apparent and similar therapeutic strategies are increasingly being applied to different
    diseases. For example, our oncology and fibrosis programs are both based upon chitinase biology. Another example is the confluence
    of thinking about immunology and oncology therapeutic approaches which led to the advent of immune checkpoint inhibitors.

    ●
    Exploiting
    multiple commercialization options to maximize each program’s value. Throughout the development of our product candidates,
    we continually assess that program’s potential paths to market, and we will endeavor to maximize commercial value through various
    options, including internal advancement, partnerships with established companies, and spin-outs or IPOs. We believe that our structure
    and operational